首页 | 本学科首页   官方微博 | 高级检索  
     


The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV
Authors:David Z. I. Cherney MD  Francesco Cosentino MD  Richard E. Pratley MD  Samuel Dagogo-Jack MD  Robert Frederich MD  Mario Maldonado MD  Jie Liu MD  Annpey Pong PhD  Chih-Chin Liu PhD  Christopher P. Cannon MD  VERTIS CV Investigators
Affiliation:1. University Health Network, University of Toronto, Toronto, Ontario, Canada;2. Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden;3. AdventHealth Translational Research Institute, Orlando, Florida, USA;4. University of Tennessee Health Science Center, Memphis, Tennessee, USA;5. Pfizer Inc., Collegeville, Pennsylvania, USA;6. MSD Limited, London, UK;7. Merck & Co., Inc., Kenilworth, New Jersey, USA;8. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Abstract:
Keywords:cardiovascular disease  diabetic nephropathy  randomized trial  SGLT2 inhibitor  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号